Updates

“The chemists here call mutated KRAS the Death Star,” says Rusty Lipford, director of inflammation and oncology research with the biotechnology firm Amgen. It’s a lethal, misshapen protein that jumpstarts a pathway that drives almost a quarter of all cancers, and it has baffled scientists who have spent almost four decades searching for weak spots in its armor.

In 2019, researchers at Amgen reported in Nature the discovery of a potential drug that chemically links to the inactive form of mutant KRAS and prevents it from shifting to its active form. It does not interfere with the functioning of normal KRAS molecules, which carry on their vital work. The compound is now in clinical trials as a potential new treatment for non-small cell lung cancer with the KRAS G12C mutation.

“KRAS has always been incredibly tough,” says Ravi Salgia, a medical oncologist at the City of Hope Comprehensive Cancer Center in Duarte, California, who has worked in the field for 30 years. “It’s really nice to see that there are now these small molecule inhibitors in clinical trials.” ... See more

"As a hematologist/oncologist specializing in lymphoma, I know that it’s possible to obtain genetic and molecular details on each patient’s cancer, and that this information can offer potentially lifesaving clues. But we don’t always know which molecular diagnostic test is appropriate for each patient.

When we do obtain genetic sequence data, it’s often unclear what it means for a patient’s prognosis. It’s hard to select the most promising medicine when different studies point to different applications. For example, several inhibitors of the enzyme anaplastic lymphoma kinase (ALK) have proven effective in treating lymphoma, non-small cell lung cancer, and neuroblastoma, while other findings suggest one of the inhibitors can treat pediatric oncology patients.

In theory, these findings should empower oncologists to find treatments that precisely fit each cancer and achieve better outcomes for patients. But in practice, oncologists are now confronted with a firehose of information that is too much to fully take in. As a result, cancer care is often not as personalized as it could be."

In Oncode, we are hematologists and oncologists best partner in precision medicine. From guiding clinicians to select the most appropriate molecular diagnostic test(s), to providing the most concise report suggesting treatment options and next steps, to technical consultation by our professional team, we support clinicians in all way possible to achieve better outcomes for patients. We know how difficult it is to apply precision medicine in actual clinical practice, and our job is to make it easier and applicable so that precision medicine can be easily accessible to all. ... See more

May the festive occasion of Dragon Boat Festival bring along lots of happiness and success for you and your dear ones.

Food and Drug Administration (FDA) has granted accelerated approval to infigratinib.

Contact us to find out how ONCODEcipher helps your physician to adapt to the latest treatment, especially in cholangiocarcinoma with a potential FGFR2 fusion or other rearrangement.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma ... See more

Food and Drug Administration (FDA) has accelerated the approval of a new first in class drug (sotorasib) for lung cancer patients.

Contact us to find out how ONCODEcipher helps your physician to adapt to the latest treatment, especially in lung cancer (potentially colorectal cancer in near future) with KRAS G12C mutation.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc ... See more

Food and Drug Administration (FDA) has accelerated the approval of a new drug (amivantamab-vmjw) for advance lung cancer patients.

Contact us to find out how ONCODEcipher helps your physician to adapt to the latest treatment, especially in advanced lung cancer with potential epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer ... See more

May this season of forgiveness bring peace to fill your heart and your home. Selamat Hari Raya Aidilfitri and happy holiday!

To all medical professionals around the world, you have been our heroes behind the scene, the answers to plenty of our medical questions, saving and impacting the lives of so many people! Let us celebrate the Medical Professional Week with pride! ... See more

Food and Drug Administration (FDA) has approved a new dosage regimen for colorectal cancer (mCRC) patients.

Contact us to find out how ONCODEcipher helps to update physician about the latest treatment planning, especially colorectal cancer patients with K-Ras wild-type & EGFR-expression.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-cetuximab ... See more